



# Captozyme

**Contact:**  
Aaron B. Cowley

**Location:**  
Gainesville, FL

**Email:**  
[aaron.cowley@captozyme.com](mailto:aaron.cowley@captozyme.com)

**Tel:**  
785.760.3128

**Website:**  
<http://www.captozyme.com>



## Company Profile

**Industry Sector:** Biotechnology

**Company Overview:** Captozyme, founded in 2009, develops novel consumer food products and therapeutics using proprietary enzymes.

The Company is dedicated to the prevention of calcium oxalate kidney stones.

In Q1 of 2017, Captozyme is introducing new foods for special dietary use and a supplement to address oxalate sensitivity. This is currently an unmet medical need, with our offering being unique and novel. Our proprietary enzymes are also being developed as stand-alone therapeutics to address more severe oxalate-related diseases.

**Target Market(s):** Kidney Stone Formers (oxalate-free foods), Recurrent Kidney Stone Formers (supplement), Primary Care Physicians and Urologists



## Key Value Drivers

**Technology:** An oxalate-degrading enzyme that degrades oxalate to formate and CO<sub>2</sub> under acidic conditions, pH 1.5-5.0. The enzyme will be used to remove oxalate from such foods as tea, beer, canned goods, flour etc., creating a line of foods coined Nephure. Similar approach as Lactaid® and Gluten-Free foods. Nephure will also be sold as a stand-alone food enzyme to remove oxalate from meals before or after being eaten. By removing oxalate in the stomach less oxalate is absorbed by the body. Thus, preventing oxalate kidney stones.

**Competitive Advantage:** (1) short path to market, (2) ability to expand into multiple product formats (3) teams experience and connections in the field.

**Plan & Strategy:** Build a brand by offering both a supplement to degrade oxalate within the stomach as well as food products that either are free or low in oxalate. Similar business model to Lactaid.



## Management

**Leadership:** The Captozyme team is lead by Aaron B. Cowley, PhD MBA (CEO), Qing-Shan Li, PhD (CSO) and Helena Cowley, MS (COO). The team has a combined knowledge of over 45 years experience which includes; best practices in enzyme and probiotic drug development, bio-analytical development, commercial scale technology transfer procedures, as well as a thorough understanding for oxalate-related conditions, the initial target patient group.

**Scientific Advisory Board:** The Scientific Advisory Board is composed of Professors and Medical Doctors at the University of Florida (Victoria and Vincent Bird, MD), University of Wisconsin (Kris Penniston), and UAB (Ross Holmes, PhD). These individuals are thought leaders in the area of oxalate-related conditions.



## Product Pipeline

**1. Pipeline One:** Food processing enzyme for removing oxalate from foods and beverages, creating a line of oxalate free foods. Captozyme, itself, plans to launch an oxalate free tea in 2016. Serviceable Obtainable Market: 25 million patients.

**2. Pipeline Two:** An enzyme supplement designed to reduce dietary oxalate in humans by degrading it in the stomach. Captozyme, itself, plans to launch this product in early 2017. Serviceable Obtainable Market: 12 million.

**3. Pipeline Three:** An enzyme replacement therapy designed to treat an enzyme deficiency in genetic disorders and thus promote healthy levels of oxalate in humans with more severe conditions, such as the rare disease condition primary hyperoxaluria. Market Size: 2000-5000.